About
Theranica develops advanced, clinically proven, safe and affordable digital therapeutics, addressing some of the world’s most prevalent neurological pain diseases.
Theranica is the developer of Nerivio, a fully integrated, self-contained family of therapeutic patches. The patches and other types of wearables in the companys pipeline are controlled by smartphone applications to easily adapt therapy treatments to everyday life. Nerivio Migra is a migraine-relief patch that provides migraine treatment through neuromodulation. Instead of placing electrodes on their head, patients can attach Theranicas clinically tested, wearable patch to their arm and launch a personalized pain-relief program.
Theranica combines electrical neurostimulation and neuromuscular stimulation technologies with modern wireless communication and smartphone applications. The company uses these advanced technologies to design and deliver effective products for treating a variety of severe and common medical problems.
In May 2019, Theranica won FDA De Novo clearance for its Nerivio Migra device. In June 2019, the company announced the establishment of a wholly owned subsidiary company, Theranica USA, headquartered in Montclair, New Jersey.
Funding history · 5 rounds · $88.1M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Theranica founded and what is its primary focus?
- Theranica was founded in November 2015 and focuses on developing advanced, clinically proven digital therapeutics for neurological pain diseases, specifically a neuromodulation-based patch for migraine relief.
- What is Theranica's flagship product and when did it receive FDA clearance?
- Theranica's flagship product is Nerivio Migra, a migraine-relief patch. It received FDA De Novo clearance in May 2019.
- When did Theranica establish its US subsidiary and where is it located?
- In June 2019, Theranica announced the establishment of its wholly owned subsidiary, Theranica USA, headquartered in Montclair, New Jersey.
- How much funding has Theranica raised in total and through which funding stage?
- Theranica has raised a total of $88.1 million USD across multiple funding rounds, reaching Series C as its current stage. For a full financing history, refer to startupim.
- When did Theranica complete its Series C funding round and who was a lead investor?
- Theranica secured its $45 million Series C funding round in August 2022, with New Rhein Healthcare Investors as a lead investor.
- Which investors participated in Theranica's Series B funding round?
- Theranica's Series B funding round in March 2019 included investors such as Omron Ventures, Corundum Open Innovation, LionBird, Takoa, Lightspeed Venture Partners, and aMoon Fund.
- What was a significant operational development for Theranica in June 2022 regarding product accessibility?
- In June 2022, Costco Wholesale Corporation added Theranica's Nerivio product to its member prescription program, expanding its accessibility.
- What recognition did Theranica's Nerivio device receive in November 2019?
- In November 2019, Theranica's Nerivio was named in TIME's List of 100 Best Inventions of 2019.
- What was the milestone achieved by Nerivio in the US by March 2021?
- By March 2021, the Nerivio drug-free wearable surpassed 100,000 migraine treatments in the US.